The Supreme Court’s decision in June 2024 in Loper Bright Enterprises v. Raimondo and Relentless Inc. v. Department of Commerce to overrule the Chevron doctrine has major implications for every administrative agency,...more
In Otsuka Pharm. Co., Ltd. v. Price, No. 16-5229 (D.C. Cir. Aug. 29, 2017), the U.S. Court of Appeals for the District of Columbia Circuit affirmed the district court decision upholding FDA’s “same moiety” test for defining...more
9/12/2017
/ Administrative Procedure Act ,
Appeals ,
Chevron Deference ,
Commercial Marketing ,
Federal Food Drug and Cosmetic Act (FFDCA) ,
First-to-File ,
Food and Drug Administration (FDA) ,
Marketing Exclusivity Periods ,
Pharmaceutical Industry ,
Pharmaceutical Patents ,
Product Exclusivity ,
Reaffirmation ,
Summary Judgment